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Abstract
Background: Racial/ethnic disparities in cardiovascular disease complications have been observed in diabetic patients. We
examined the association between race/ethnicity and cardiovascular disease risk factor control in a large cohort of insulin-
treated veterans with type 2 diabetes.
Methods:  We conducted a cross-sectional observational study at 3 Veterans Affairs Medical Centers in the American
Southwest. Using electronic pharmacy databases, we randomly selected 338 veterans with insulin-treated type 2 diabetes. We
collected medical record and patient survey data on diabetes control and management, cardiovascular disease risk factors,
comorbidity, demographics, socioeconomic factors, psychological status, and health behaviors. We used analysis of variance and
multivariate linear regression to determine the effect of race/ethnicity on glycemic control, insulin treatment intensity, lipid
levels, and blood pressure control.
Results: The study cohort was comprised of 72 (21.3%) Hispanic subjects (H), 35 (10.4%) African Americans (AA), and 226
(67%) non-Hispanic whites (NHW). The mean (SD) hemoglobin A1c differed significantly by race/ethnicity: NHW 7.86 (1.4)%,
H 8.16 (1.6)%, AA 8.84 (2.9)%, p = 0.05. The multivariate-adjusted A1c was significantly higher for AA (+0.93%, p = 0.002)
compared to NHW. Insulin doses (unit/day) also differed significantly: NHW 70.6 (48.8), H 58.4 (32.6), and AA 53.1 (36.2), p <
0.01. Multivariate-adjusted insulin doses were significantly lower for AA (-17.8 units/day, p = 0.01) and H (-10.5 units/day, p =
0.04) compared to NHW. Decrements in insulin doses were even greater among minority patients with poorly controlled
diabetes (A1c ≥ 8%). The disparities in glycemic control and insulin treatment intensity could not be explained by differences in
a g e ,  b o d y  m a s s  i n d e x ,  o r a l  h y p o g l y c e m i c medications, socioeconomic barriers, attitudes about diabetes care, diabetes
knowledge, depression, cognitive dysfunction, or social support. We found no significant racial/ethnic differences in lipid or
blood pressure control.
Conclusion: In our cohort, insulin-treated minority veterans, particularly AA, had poorer glycemic control and received lower
doses of insulin than NHW. However, we found no differences for control of other cardiovascular disease risk factors. The
diabetes treatment disparity could be due to provider behaviors and/or patient behaviors or preferences. Further research with
larger sample sizes and more geographically diverse populations are needed to confirm our findings.
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Background
Type 2 diabetes causes a substantial burden of suffering
for minorities. Compared to non-Hispanic whites, all
minorities except Alaskan natives have a 2- to 6-fold
increased risk of acquiring the disease [1-3], and the prev-
alence is rising in some groups, including African Ameri-
cans, Hispanic Americans, and American Indians [4].
Many population studies have shown that minorities do
not achieve the same level of glycemic control as non-His-
panic whites [3,5-8]. Cultural and socioeconomic differ-
ences may create barriers to health by making it difficult
to adhere to customary self-care recommendations for
diet, weight loss, exercise, or blood glucose monitoring
[1,2,9-11]. Finally, minorities have been shown to have
an increased risk of developing micro- or macrovascular
disease complications [1,12,13]. An excess risk has been
described for nephropathy [3,14-16], retinopathy [17-
19], amputations and foot problems [1,20], coronary
artery disease [3], and stroke [3,21] compared to non-His-
panic whites. This health care burden makes it imperative
to develop appropriate interventions for minority
patients.
Evaluating racial and ethnic variations in the intermediate
outcomes of diabetes care may be the best way to assess
diabetes management. A comprehensive evaluation is
essential because socio-cultural barriers may differentially
influence various clinical outcomes. Evaluations should
encompass weight control, diet, exercise, glycemic con-
trol, smoking status, lipid management, and blood pres-
sure control. The American Southwest is an appropriate
region for evaluating racial and ethnic differences in dia-
betes care because of the high prevalence of disease and
the large minority populations. The purpose of this study
was to examine the association between race/ethnicity
and control of cardiovascular disease risk factors, adjusted
for socioeconomic, clinical, and behavioral factors, in a
large cohort of insulin-treated veterans with type 2 diabe-
tes.
Methods
The Diabetes Outcomes in Veterans Study (DOVES) was a
prospective, observational study of insulin-treated veter-
ans with type 2 diabetes mellitus, designed to examine the
association between clinical, demographic, lifestyle, soci-
oeconomic, and psychological variables and the clinical
outcomes of glycemic control and disease management.
DOVES was conducted under the auspices of the South-
western Group for Outcomes Research in Diabetes
(SWORD), a consortium of the largest VA facilities in Vet-
erans Integrated Service Network 18. The protocol for this
study was described in detail elsewhere [22]. The institu-
tional review board of each study site approved the proto-
col. Briefly, computerized pharmacy records were used to
identify insulin-treated patients receiving care at the New
Mexico VA Health Care System (Albuquerque, NM), the
Carl T. Hayden VA Medical Center (Phoenix, AZ), and the
Southern Arizona VA Health Care System (Tucson, AZ).
Patients were eligible for this study if they had type 2 dia-
betes diagnosed after age 35; took at least daily one injec-
tion of a long-acting insulin preparation, did not self-
titrate their insulin doses; and their diabetes medication
regimen had been relatively unchanged in the preceding 2
months (the dose of all oral hypoglycemic medications
remained unchanged, no oral hypoglycemic medications
were added to the treatment regimen, and the total daily
insulin dose was changed by no more than 10 units or
15%, whichever was less), thus ensuring that their A1c
had equilibrated at the current insulin dose.
We excluded patients with less than a one-year expected
survival; alcoholism or substance abuse listed as an active
problem in the electronic medical record; a history of dia-
betic ketoacidosis or type I diabetes; or co-morbidities
affecting glucose homeostasis: diabetes resulting from
pancreatitis or pancreatic resection; cirrhosis, chronic
active hepatitis, hemochromatosis, Wilson's disease or
other liver disease; endocrinopathies such as pituitary
adenoma, Cushing's or Addison's disease; hereditary or
acquired forms of insulin resistance; glucocorticoid treat-
ment; immunosuppression or treatment with immuno-
suppressant drugs; or chronic infectious diseases (e.g.
osteomyelitis or refractory skin ulcers). We also excluded
homeless patients because they would have difficulty with
the intensive self-monitoring of blood glucose required
for the DOVES prospective study.
All measures in this report were collected at the two base-
line visits, scheduled two weeks apart, with the exception
of insulin doses measured at a 26-week follow-up visit. At
the entry visit, research coordinators explained the
project, answered questions, and obtained informed con-
sent. All subjects underwent an evaluation of their psy-
chological status, socio-cultural barriers to diabetes
management, disabilities, dietary habits, exercise patterns,
and micro- and macrovascular disease risk factors. Race/
ethnicity was determined from a structured category ques-
tion that asked the patient to describe his or her back-
ground. The listed responses included non-Hispanic
white, Hispanic, Native American, African-American, and
Asian. Subjects also had the option to check an "other"
category and write in a response. Subjects then answered
questions on their family obligations, living arrange-
ments, means of transportation, occupation, and finan-
cial status. Subjects rated their physical ability to do the
following activities: work, yard work, household projects,
shopping, exercise, cooking or light housekeeping, and
personal care. Research coordinators conducted struc-
tured interviews with study subjects to collect data about
medical treatment, including insulin dose, number ofBMC Health Services Research 2006, 6:58 http://www.biomedcentral.com/1472-6963/6/58
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injections, types of preparations, and the dose, type, and
frequency of use of oral hypoglycemic medications.
Research coordinators then ascertained the number of
units of each insulin type at each daily dosing time and
summed them to determine total insulin units per day.
Psychosocial testing was performed in private sessions
during the baseline visit and the second visit two weeks
later. A research coordinator was present to provide
instructions, answer questions, clarify items, or in some
cases, read the questions. Psychological instruments were
administered in random order and included the Univer-
sity of Michigan Diabetes Knowledge Test [23], the Mini-
Mental State Examination (MMSE) [24], the Geriatric
Depression Scale [25], the Diabetes Family Behavior
Check List [26], and the Diabetes Care Profile [27]. We
used the Compendium of Physical Activities to rate phys-
ical activities [28] and the Fred Hutchinson Cancer
Research Center Food Frequency Analysis to assess dietary
habits [29]. Baseline physiologic measurements made
upon entry to the study included hemoglobin A1c (A1c),
blood pressure, height, weight, smoking status, and blood
lipids.
Statistical analyses
We analyzed group differences in continuous variables by
the unpaired Student's t-test and one-way analysis of var-
iance. For the latter procedure, homogeneity of variances
was examined by Levene's test, and the Brown-Forsythe
test was used in place of the standard ANOVA F-test if the
variances were significantly different (performed on
BMDP software). The Mann-Whitney U-test and the
Kruskal-Wallis one-way analysis of variance by ranks were
used for variables with highly skewed distributions.
Group differences in nominal variables were tested by chi-
square analysis. The relationship between continuous var-
iables was examined by simple regression. We used step-
wise multiple linear regression analyses to identify factors
affecting the baseline A1c and daily insulin doses. Predic-
tors associated with the dependent variable in univariate
analysis (p < 0.10) were entered into multivariate model
using a forward- and backward-stepping procedure with
an α ≤ 0.05 to enter and an α > 0.10 to remove. Continu-
ous variables were expressed as mean ± standard deviation
(SD).
Results
We identified over 10,000 insulin-treated patients at the
three participating medical centers. We randomly selected
approximately 3000 subjects from this list and invited
589 eligible subjects to participate. We enrolled 359
(61%) subjects, but subsequently excluded 21 with
incomplete data, leaving a cohort of 338 for the analysis.
Their mean age was 65.1 ± 9.7 years, 96% were men, and
59% were married. Based on self-description, the cohort
was comprised of 226 (67%) non-Hispanic white, 72
(21%) Hispanic, and 35 (10%) African-American sub-
jects. Over two-thirds of the subjects had at least one
microvascular disease complication and an equivalent
number had a macrovascular disease complication.
Although average daily insulin doses were substantial (66
units), only one-third of the subjects were concurrently
treated with an oral hypoglycemic medication. Most sub-
jects had an elevated baseline A1c value suggesting poor
glycemic control, including 99 (29%) with a value
between 7.0% and 8.0%, and 148 (44%) with a value ≥
8.0%. The median level of activity was 7 met-hours of
activity per day (equivalent to 2.5 hours of light home
activities plus 0.5 hours of moderate walking). Sixty-two
percent had a BMI ≥ 30 and 22.2% were current smokers.
However, average lipid and blood pressure measurements
were close to the target values recommended by the Amer-
ican Diabetes Association (ADA) [30,31].
Clinical and socioeconomic characteristics stratified by
race/ethnicity are presented in Table 1. African-American
subjects had the highest A1c and were most likely to have
poor glycemic control. Fifty-one percent of African Amer-
icans had an A1c ≥ 8% compared to 49% for Hispanics
and 40% for non-Hispanic whites (p = 0.27). Mean ± SD
A1c levels were 7.9 ± 1.4% for non-Hispanic whites, 8.2 ±
1.6% for Hispanics, and 8.8 ± 2.9% for African Americans
(P = 0.05). We found significant differences in the daily
units of insulin, with non-Hispanic whites receiving 70.6
± 48.8 units compared to 58.4 ± 32.6 units for Hispanics
and 53.1 ± 36.2 units for African Americans (p < 0.01).
However, we found no differences between minorities
and non-Hispanic whites in the daily number of insulin
injections, the number of different insulin preparations
used, or the use of oral hypoglycemic medications. Body
mass index, amount of exercise, smoking status, lipid lev-
els, and blood pressures were also similar between groups.
We also evaluated potential barriers to care. African-Amer-
ican subjects considered themselves less disabled for work
(Table 1). Hispanic subjects had the most dependents,
and reported the highest psychosocial barriers with
respect to language preference, education, depression,
diabetes knowledge, and performance on the MMSE
(Table 2). African-Americans perceived the fewest prob-
lems with glycemic control, had the fewest negative atti-
tudes about diabetes, and had the highest self-ratings for
self-care abilities and dietary adherence. They also tended
to have the strongest convictions about the importance of
self-care and the fewest perceived barriers to exercise.
We found that higher depression scores (r = 0.11, p =
0.049), greater work hours per week (r = 0.17, p = 0.002),
greater number of household dependents (r = 0.13, p =
0.023), being employed (p = 0.004), and age (r = -0.21, pBMC Health Services Research 2006, 6:58 http://www.biomedcentral.com/1472-6963/6/58
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= 0.0001) were significantly associated with a higher base-
line A1c. After adjusting for these covariates with a multi-
variate linear regression analysis, baseline A1c was
significantly higher for African-American subjects
(+0.93%, p = 0.002), though not for Hispanics (+0.25%,
p = 0.29), compared to non-Hispanic whites.
We stratified daily insulin dose by race and ethnicity and
level of glycemic control (Table 3). We found that unad-
justed daily insulin units increased monotonically with
A1c in non-Hispanic whites, but not in Hispanics or Afri-
can Americans. We found the most significant racial/eth-
nic differences in insulin doses among subjects with
poorly controlled diabetes (A1c ≥ 8.0%), with non-His-
panic whites receiving approximately 22 daily units more
than Hispanics and 26 daily units more than African
Americans (p < 0.01). At follow-up, the treatment patterns
remained essentially the same. Overall, 63% of each
minority group and 70% of the non-Hispanic whites
returned for the 26-week follow-up visit. For non-His-
panic whites, Hispanics, and African Americans, the mean
± SD daily insulin units were 71.1 ± 51.2, 63.1 ± 36.9, and
51.4 ± 26.6, respectively (p = 0.14). Among subjects with
a baseline A1c ≥ 8.0%, the mean ± SD daily insulin units
at follow-up also differed significantly (p = 0.04): non-
Hispanic whites = 80.3 ± 51.3, Hispanics = 63.0 ± 34.0,
and African Americans = 47.8 ± 23.1.
We found that race/ethnicity, BMI, baseline A1c, and use
of any other oral hypoglycemic medication were signifi-
cant predictors of daily insulin units on multivariate lin-
ear regression analyses (Table 4). African-Americans
received an insulin dose that was an average of 17.8 units
less (P = 0.01) and Hispanics an average of 10.5 units less
Table 1: Sociodemographic and clinical features by race and ethnicity.
Non-Hispanic white (n = 226) Hispanic (n = 72) African-American (n = 35) P-value
Demographics
Age: mean ± SD years 65.5 ± 9.4 64.9 ± 10.1 63.3 ± 10.8 NS
Female 5.3% 1.4% 0% NS
Married 56.6% 66.7% 62.9% NS
Disease history
Diabetes duration: mean ± SD years 14.1 ± 9.5 15.4 ± 10.5 15.5 ± 10.6 NS
Duration of medical treatment: mean ± SD years 12.3 ± 9.0 14.1 ± 10.5 12.6 ± 10.0 NS
Duration of insulin treatment: mean ± SD years 8.0 ± 7.7 7.8 ± 8.1 8.6 ± 8.2 NS
Complications
Neuropathy 59.7% 63.9% 51.4% NS
Peripheral vascular disease 35.8% 41.7% 28.6% NS
Angina or chest pain 35.0% 23.6% 40.0% NS
Myocardial infarction 33.6% 26.4% 17.1% NS
Retinopathy 31.9% 21.4% 34.3% NS
Stroke 13.7% 13.9% 11.4% NS
Extremity amputation 6.6% 8.3% 14.3% NS
Chronic renal disease 3.5% 0% 2.9% NS
Blindness 1.3% 1.4% 0% NS
Any microvascular complication 67.7% 69.4% 71.4% NS
Any macrovascular complication 66.4% 61.1% 57.1% NS
Disabilities
Work 55.8% 55.6% 31.4% 0.03
Household projects 56.6% 47.2% 45.7% NS
Yard work 40.3% 33.3% 25.7% NS
Exercise 28.4% 19.4% 25.7% NS
Cooking 11.1% 9.7% 5.7% NS
Shopping 9.7% 12.5% 11.4% NS
Self-care 4.0% 5.6% 2.9% NS
Any of the above 72.1% 73.6% 54.3% NS
Another person:
Measures blood sugars 1.3% 0% 5.7% NS
Administers insulin 4.0% 0% 5.7% NS
Family circumstances
Head of household 89.3% 97.2% 94.3% NS
Size of household: mean ± SD 1.96 ± 1.16 2.35 ± 1.60 2.03 ± 0.92 0.04
Number of dependents: mean ± SD 0.57 ± 0.90 0.83 ± 0.90 0.69 ± 0.80 0.02
Family member with alcoholism 6.6% 2.8% 8.6% NSBMC Health Services Research 2006, 6:58 http://www.biomedcentral.com/1472-6963/6/58
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(P = 0.04) than non-Hispanic whites. No significant inter-
actions were observed. When the adjusted model was lim-
ited to those with baseline A1c ≥ 8%, African-Americans
received an insulin dose that was an average of 26.5 units
less (P = 0.01) and Hispanics an average of 15.9 units less
(P = 0.03) than non-Hispanic whites. These differences
persisted after adjusting for practice site.
Discussion
We evaluated racial/ethnic differences in glycemic con-
trol, medical therapy, and control of cardiovascular dis-
ease risk factors in insulin-treated Southwest American
veterans with type 2 diabetes. We found that African
Americans and Hispanics had poorer glycemic control
and received less intensive insulin treatment, particularly
African-Americans with A1c ≥ 8.0% who received over 25
units of insulin less per day less than non-Hispanic
whites. We found that blood lipids and blood pressure
control were close to ADA target values for all racial/eth-
nic groups. This finding is consistent with previous find-
ings that failure to intensify insulin treatment contributed
to poor glycemic control in urban African-Americans [32].
This under-treatment is an important health problem, as
evidence suggests that African Americans respond better
to insulin treatment [33].
Several psychosocial factors and barriers to care or self-
care varied among the racial/ethnic groups in this study,
and could be related to the observed disparities in glyc-
emic control. Hispanics were the most disadvantaged
Table 2: Psychological features by race and ethnicity*.
Non-Hispanic white (n = 226) Hispanic (n = 72) African-American (n = 35) P-value
Preference for English 98.7% 83.3% 100% <0.001
Education (years) 13.7 ± 2.8 11.9 ± 4.0 12.9 ± 2.0 <0.001†
Cognitive Deficit mean§ 28.3 ± 2.0 26.4 ± 3.5 27.7 ± 1.8 <0.001
Family Behavior Checklist score|| 6.16 ± 6.92 6.33 ± 6.88 8.26 ± 5.92 NS
Diabetes Knowledge score¶ 67.4 ± 13.9 56.3 ± 17.0 62.1 ± 16.8 <0.001
Depression score** 7.60 ± 6.58 9.42 ± 7.14 6.03 ± 5.63 0.03‡
Diabetes Care Profile scores††
Problems with glycemic control 3.98 ± 0.66 3.93 ± 0.56 4.27 ± 0.58 0.02‡
Social and personal impact 3.47 ± 0.82 3.39 ± 0.84 3.73 ± 0.72 NS
Positive attitudes 3.10 ± 0.72 2.99 ± 0.72 3.12 ± 0.94 NS
Negative attitudes 3.53 ± 0.80 3.24 ± 0.90 3.80 ± 0.83 0.008‡
Perceived ability to do self-care 3.00 ± 0.74 3.00 ± 0.87 3.53 ± 0.74 0.001‡
Importance of self-care 4.24 ± 0.58 4.29 ± 0.62 4.45 ± 0.66 NS
Adherence to self-care 3.49 ± 0.74 3.51 ± 0.77 3.80 ± 0.79 NS
Adherence to diet 2.65 ± 0.94 2.65 ± 0.96 3.08 ± 0.81 0.04‡
Barriers to taking medications 4.57 ± 0.45 4.55 ± 0.56 4.59 ± 0.52 NS
Barriers to exercise 4.04 ± 0.80 4.04 ± 0.80 4.37 ± 0.64 NS
Barriers to monitoring 4.63 ± 0.46 4.50 ± 0.60 4.38 ± 0.83 NS
Understanding of objectives 3.44 ± 0.81 3.22 ± 0.81 3.57 ± 0.83 NS
Perception of long-term benefits 4.38 ± 0.68 4.29 ± 0.86 4.15 ± 0.96 NS
Social support 3.82 ± 0.60 3.87 ± 0.63 3.94 ± 0.63 NS
* Values are mean ± SD unless otherwise indicated
†Brown-Forsythe test
‡Kruskal-Wallis one-way analysis of variance by ranks
§Mini-Mental State Examination: 30-point scale, higher score more favorable
||Scale ranging from -44 to 38, higher score more favorable
¶ University of Michigan Diabetes Knowledge Test: percentage correct, higher score more favorable
**Geriatric Depression Scale: 30-point scale, lower score more favorable
†† Scale ranging from 1 to 5, higher score more favorable
Table 3: Daily insulin units by baseline hemoglobin A1c and race/ethnicity
A1c category Non-Hispanic white Hispanic African-American All subjects
NM e a n  ±  S D  
daily units
NM e a n  ±  S D  
daily units
NM e a n  ±  S D  
daily units
N Mean ± SD 
daily units
< 7.0% 66 62 ± 52 14 54 ± 39 11 56 ± 50 91 60 ± 49
7.0%–7.9% 69 68 ± 46 22 63 ± 34 6 50 ± 22 98 66 ± 42
≥ 8.0% 91 79 ± 48 35 57 ± 29 18 53 ± 31 144 70 ± 44BMC Health Services Research 2006, 6:58 http://www.biomedcentral.com/1472-6963/6/58
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group in terms of language preference and education and
scored higher on the depression inventory. These factors
may explain their performance on the MMSE and Diabe-
tes Knowledge tests – tasks that required comprehension
of complex instructions. On the other hand, African-
Americans had more favorable responses in several areas
rated by the Diabetes Care Profile. We could not readily
attribute poorer glycemic control to a negative outlook in
this group.
Other investigators have found that racial/ethnic differ-
ences in attitudes towards type 2 diabetes might contrib-
ute to poor outcomes [34,35]. Possibly, instruments
specifically developed for that purpose might have
explained some of the effects of race/ethnicity on glycemic
control and treatment intensity. For example, the Veterans
Ecocultural Self Report [36] adaptation measure better
explains the effect of minority status on glycemic control
than does Hispanic ethnicity. Our inability to identify
these factors may also be due to the fact that our instru-
ment did not specifically target insulin therapy. Hunt and
associates [37] used an open-ended interviewing tech-
nique to examine the attitudes of 44 low-income Mexican
Americans towards insulin therapy. Negative aspects were
much more frequently discussed than positive aspects and
focused on anxiety about pain, proper techniques, dis-
rupting daily activities, low blood sugars, and other com-
plications of therapy. The subjects also expressed concern
that previous treatment efforts had failed and that the dis-
ease had progressed into a more serious phase. Our study
suggests that integrating an abbreviated interview tech-
nique could be considered for future studies of minority
subjects with an inadequate response to insulin therapy.
Potential cultural barriers to a more intensive insulin reg-
imen in minorities also include: 1) a greater aversion to
parenteral injections or to multiple injections; 2) greater
fear of hypoglycemic events; 3) greater aversion to glucose
monitoring; and 4) cultural barriers relating to images of
wellness, such as a cultural aversion to public display of
illness.
This study has some potential limitations. We cannot
explain why minorities with poor glycemic control did
not receive higher insulin doses. One possibility is a selec-
tion bias that precluded the enrollment of minorities with
more aggressive insulin regimens and better glycemic con-
trol. We randomly selected subjects from a sample frame
generated from administrative pharmacy files; however, a
number of eligible patients refused to participate. Because
participation in this study required time, travel, disrup-
tion of daily routines, and some discomfort, even minor
cultural barriers may have played a role in the loss of more
intensively-treated minorities. We were unable to ascer-
tain the race/ethnicity of non-participants. Since provider
adjustments to insulin dose are not captured in the
administrative pharmacy database, we relied on self-
report from patients for current insulin units per day via
structured interviews with research coordinators. While
this was the best practical source of information, it is pos-
sible that minority patients systematically under-reported
their insulin dose. Another possibility for the difference in
treatment intensity is that minority patients had fewer
clinic visits. We were unable to assess this because we did
not have data on the number of clinic visits since being
started on insulin. However, it is unlikely that an effect
from fewer visits would persist over an average of 8 years
of insulin treatment. Additionally, given the equal access
to VA health care shared by all veterans, the frequency of
clinic visits would not likely be an explanation for differ-
ential treatment, but rather a marker for confounding
socioeconomic or psychological factors. Finally, because
of the population studied, our results may be less general-
izable to younger patients, non-veterans, or women.
Insulin treatment may have been less intensive in minor-
ities for clinical reasons. Hypoglycemia is a major deter-
rent to tight glycemic control. Although age has been
identified as a risk factor for drug-induced hypoglycemia
[38], the roles of race and ethnicity have not been estab-
lished. Possibly, some providers perceive a higher
hypoglycemia risk for minority patients that may affect
treatment intensity. This hypothesis requires further eval-
uation. The risk of hypoglycemia could be affected by die-
tary habits that are influenced by race and culture.
Another possibility is racial/ethnic differences in the
intensity of glucose monitoring. Because monitoring is
used to titrate insulin doses, targets may not have been
reached in those who tested less frequently. In 1993, Har-
ris and co-workers [39] reported data from the 1989
National Health Interview Survey on 2,405 diabetic
patients ≥ 18 years of age. They found that African-Amer-
icans were 60% less likely to test their blood glucose at
least once daily compared to non-Hispanic whites and
Table 4: Regression model predicting daily insulin units.
Predictor Coefficient 95% Confidence Interval P value
Hispanic* -10.5 -20.6, -0.46 0.04
African American* -17.8 -31.4, -4.3 0.01
BMI† (kg/m2) 3.4 2.7, 4.2 < 0.001
Baseline A1c‡ (%) 3.0 0.50, 5.5 0.02
Age (years) -0.36 -0.81, .094 0.12
Metformin -9.1 -20.1, 1.9 0.10
Other OHM§ -32.0 -42.4, -21.5 < 0.001
Constant -30.6 -80.7, 19.5 0.23
Number of observations = 327, R2 = 0.336 (P < 0.0001)
* Effect in reference to non-Hispanic whites
† Body Mass Index
‡ Hemoglobin A1C
§Oral hypoglycemic medicationBMC Health Services Research 2006, 6:58 http://www.biomedcentral.com/1472-6963/6/58
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Hispanics. The effect of race/ethnicity was independent of
age, insulin use, education, intensity of physician visits, or
diabetes education. Unfortunately, we did not obtain
information on monitoring practices or the rate of
hypoglycemia when patients entered this study.
Finally, it should be noted that the differences among the
racial/ethnic groups were limited to insulin use. We found
no racial/ethnic differences in the use of oral hypoglyc-
emic medications or in the control level of 5 other risk fac-
tors for cardiovascular disease (weight exercise, smoking
status, lipids, and blood pressure). In contrast, Heisler
and co-workers [40] found that African American veterans
with type 2 diabetes were more likely to have poor lipid
and blood pressure control compared to white veterans,
although there was no difference in intensity of treatment
for those in poor control (the intensity of the glycemic
regimen was not measured). Our study may have been
underpowered to detect small differences in lipids, blood
pressure, and other risk factors. However, the finding of
comparable control across racial/ethnic groups suggests
that subjects did not face substantial access barriers and
that providers were addressing these cardiovascular risk
factors. However, glycemic control and insulin treatment
require more motivation and patient education than
other aspects of cardiovascular disease risk factor control.
Failure to achieve treatment goals may have been due to
specific problems with the patient-provider interaction.
One possibility is that the patient was not able to establish
an effective therapeutic relationship with a provider of
another race. A second possibility is that the providers
were not aware of the specific needs of minorities with
diabetes [41]. Providers often address multiple acute and
chronic conditions during medical encounters; this may
present a barrier for consistently providing preventive
services and optimal disease management for diabetes,
particularly if minority patients have more comorbidity
than non-Hispanic white patients [42,43]. Although pro-
vider effects are an important determinant of diabetes
control, we did not have sufficient power to model this
factor in our analyses.
Conclusion
In summary, insulin-treated veterans who are minorities
may have an increased risk of poor glycemic control and
receiving lower doses of insulin. African-Americans in this
sample were the most likely patients to experience this
problem, while Hispanics had an intermediate risk. No
racial or ethnic differences were found for the control of
other cardiovascular disease risk factors. The disparities in
glycemic control and treatment intensity could not be
explained by the socioeconomic barriers, attitudes, level
of knowledge, depression, cognitive dysfunction, or social
support rated by the instruments in this study. The treat-
ment disparity could be due to provider behaviors and/or
patient behaviors or preferences. Further research with
larger sample sizes and more geographically diverse pop-
ulations are needed to confirm our findings and to eluci-
date the reasons for any observed disparities.
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